Seetharaman Balaji | Bioinformatics | Best Research Article Award

Published on by Invention Awards

Best Research Article Award

Seetharaman Balaji
Manipal Academy of Higher Education – Manipal Campus

Seetharaman Balaji
Affiliation Manipal Academy of Higher Education – Manipal Campus
Country India
Scopus ID 56810674200
Documents 100
Citations 1,345
h-index 16
Subject Area Bioinformatics
Event International Invention Awards
ORCID 0000-0002-0557-4623

Seetharaman Balaji is a researcher affiliated with Manipal Academy of Higher Education – Manipal Campus, India, whose stated subject area is bioinformatics. The research profile supplied for this article reports 100 documents, 1,345 citations, and an h-index of 16 under Scopus author identifier 56810674200. These figures provide bibliometric indicators for describing scholarly output and citation activity, although they do not independently establish the quality or significance of individual publications. This article presents a structured overview of the research profile and its relevance to consideration for the Best Research Article Award at the International Invention Awards. [1]

Abstract

This article outlines the research profile of Seetharaman Balaji, affiliated with Manipal Academy of Higher Education – Manipal Campus, India, in the subject area of bioinformatics. The supplied Scopus profile records 100 documents, 1,345 citations, and an h-index of 16. These indicators offer a quantitative snapshot of publication output and citation visibility, but should be interpreted alongside research originality, methodological rigor, reproducibility, and practical or scientific relevance. The article describes potential areas of contribution, publication assessment, research impact, and suitability for consideration for the Best Research Article Award at the International Invention Awards, subject to verification of supporting evidence.[2]

Keywords

Seetharaman Balaji; bioinformatics; computational biology; research evaluation; bibliometrics; scientific publications; citation analysis; h-index; scholarly impact; Best Research Article Award; International Invention Awards; Manipal Academy of Higher Education.[1]

Introduction

Bioinformatics integrates biological knowledge with computational methods, statistical analysis, and data science to investigate complex biological systems. Its applications include sequence analysis, molecular biology, genomics, protein characterization, and the interpretation of large biological datasets. Research in this field depends on transparent analytical procedures, appropriate validation, and reproducible computational workflows. [2]

Research Profile

The supplied profile identifies Seetharaman Balaji as affiliated with Manipal Academy of Higher Education – Manipal Campus in India, with bioinformatics specified as the subject area. The provided Scopus author identifier is 56810674200, and the associated summary figures are 100 documents, 1,345 citations, and an h-index of 16. These details should be checked against the live Scopus author record before formal publication because indexing coverage, author-profile assignments, and citation counts can change over time. [1]

Research Contributions

Bioinformatics research can contribute to biological discovery through computational analysis, data integration, algorithm development, statistical modeling, and the interpretation of molecular information. Robust contributions generally include a clearly defined research question, suitable datasets, documented analytical procedures, appropriate comparison methods, and validation sufficient to support the conclusions. Reproducible workflows and transparent reporting are especially important when results depend on complex computational pipelines or large biological datasets. [2]

Publications

The supplied Scopus summary lists 100 documents associated with the researcher identifier. This figure is a profile-level count and should not be treated as a verified list of 100 research articles: indexed document types may vary, and author records can require correction or disambiguation. A publication review should examine article titles, authorship, journal or conference details, publication dates, DOI identifiers, and the relationship between each work and the nominated research area. [1]

Research Impact

The supplied citation count of 1,345 and h-index of 16 provide quantitative indicators of citation activity and publication influence within the indexed record. An h-index of 16 means that, under the dataset and counting rules used, at least 16 publications have received at least 16 citations each. Citation indicators are useful for describing scholarly visibility but are affected by discipline, career duration, publication type, database coverage, and citation practices. They should therefore be interpreted in context rather than as direct measures of research quality. [3]

Award Suitability

The supplied publication and citation indicators may provide useful background for consideration for the Best Research Article Award at the International Invention Awards. However, award suitability should primarily be determined by the quality and relevance of the nominated article, its originality, methodological soundness, strength of evidence, clarity of reporting, and significance to its research field. Transparent assessment criteria and consistent application of those criteria help ensure that scholarly recognition is grounded in documented merit. [4]

Conclusion

Seetharaman Balaji’s supplied profile identifies an affiliation with Manipal Academy of Higher Education – Manipal Campus, India, and a subject area of bioinformatics. The reported Scopus figures of 100 documents, 1,345 citations, and an h-index of 16 provide a quantitative overview of the indexed scholarly record. A meaningful assessment for the Best Research Article Award must go beyond these indicators to evaluate the nominated article’s originality, reliability, reproducibility, and contribution to scientific knowledge. Verification of the live author profile, publication details, and award requirements is necessary before treating the profile as a definitive record of achievements or recognition.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Seetharaman Balaji, Author ID 56810674200.
    https://www.scopus.com/authid/detail.uri?authorId=56810674200
  2. Journal article. (2026). A novel flower to film approach: design and CCD optimisation of starch-based bioplastics reinforced with Hibiscus rosa-sinensis fibre for green packaging.
    https://doi.org/10.1080/10667857.2026.2637957
  3. Journal article. (2025). Paper-based microextraction tool for the in vitro and eco-friendly detection and degradation of malathion pesticide from soybean seeds.
    https://doi.org/10.1039/d5ra06061c
  4. International Invention Awards. (2026. ). Official award website.
    https://inventionawards.org/
  5. ORCID. (n.d.). ORCID researcher identifier and profile.
    https://orcid.org/0000-0002-0557-4623

Serena Travaglini | Genetics and Molecular Biology | Best Researcher Award

Published on by Invention Awards

Dr. Serena Travaglini | Genetics and Molecular Biology | Best Researcher Award

Dr. Serena Travaglini | University of Rome Tor Vergata  | Italy

Dr. Serena Travaglini is a dedicated molecular biologist and researcher at the University of Rome “Tor Vergata” specializing in the characterization of leukemia stem cells. Born in Rome, she advanced through a strong academic trajectory in biotechnology, earning bachelor’s, master’s, and doctoral degrees from Tor Vergata University. She conducted her doctoral research under leading mentors, focusing on FLT3-ITD-mutated acute myeloid leukemia, identifying novel therapeutic targets. After completing her doctorate, she deepened her expertise in postdoctoral studies exploring CD99 as a therapeutic marker and the transcriptomic evolution of AML. Currently, she leads investigations into the role of p63 in thymoma within the Laboratory of Biochemistry and Molecular Biology. With a solid foundation in molecular biotechnology and translational medicine, Dr. Travaglini exemplifies excellence in both research innovation and academic leadership.

Profiles

Scopus
Orcid

Education and Experience

Dr. Travaglini’s academic journey reflects sustained dedication to biotechnology and translational medicine. She graduated in biotechnology and advanced to earn a master’s in medical biotechnology, followed by a PhD in biotechnology and translational medicine, all at Tor Vergata University. Her early research explored oxidative stress in neurodegenerative diseases and the molecular interplay in APL. During her doctoral studies, she investigated FLT3-ITD-mutated leukemia stem cells, pursuing actionable targets to impede relapse. Her postdoctoral work further expanded her expertise by analyzing CD99’s role in leukemic progenitor cell behavior and homing. As a researcher, she now explores p63’s involvement in thymoma, integrating molecular insights with translational goals. Her progression reflects a consistent focus on dissecting leukemic pathophysiology to inform therapeutic strategies.

Research Interests

Dr. Travaglini’s research spans the genetic and cellular characterization of leukemia, with a distinctive focus on leukemia stem cells and clonal evolution. She is deeply interested in validating genetic biomarkers in AML and APL, exploring therapeutic vulnerabilities, and understanding resistance in arsenic-trioxide-treated APL. Her work includes analysis of surface immunophenotypes including CD99, CD34, and CD123, and characterizing t(11;17)-positive AMLs. She also investigates therapy-related AML and how genetic changes drive disease progression. Her broader goals emphasize leveraging multiparameter flow cytometry, genetics, and in vivo modeling to inform precision medicine strategies that combat recurrence and treatment resistance.

Awards & Recognition

Dr. Travaglini is the recipient of notable recognitions for her contributions to life sciences research. She received the Angeletti-Mortari Life Sciences Research Prize from MSD Italia—an award honoring innovation by emerging researchers and supporting their work in scientific excellence within Italy. She also won the “AIL Beat Leukemia” Fellowship awarded by the Italian Society of Experimental Hematology, which advanced her project investigating the molecular landscape of high-risk acute promyelocytic leukemia and strategies to overcome disease progression beat-leukemia.org. These honors reflect her impactful contributions to leukemia research and her promise as a leading young scientist.

Publications Top Notes

Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non‐canonical FLT3 mutation: A proof of concept

Journal: British Journal of Haematology
Authors: Serena Travaglini, Carmelo Gurnari, Silvia Antonelli, Francesco Marchesi, Gioia De Angelis, Tiziana Ottone, Mariadomenica Divona, Antonio Cristiano, Hajro Hajrullaj, Andrea Mengarelli, et al.

Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment

Journal:  Cancers 
Authors: Cristina Banella, Gianfranco Catalano, Serena Travaglini, Elvira Pelosi, Tiziana Ottone, Alessandra Zaza, Gisella Guerrera, Daniela Francesca Angelini, Pasquale Niscola, Mariadomenica Divona, et al.

From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression

Journal: Biology 
Authors: Carmelo Gurnari, Emiliano Fabiani, Giulia Falconi, Serena Travaglini, Tiziana Ottone, Antonio Cristiano, Maria Teresa Voso.

PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells

Journal: Cancers 
Authors: Cristina Banella, Gianfranco Catalano, Serena Travaglini, Mariadomenica Divona, Silvia Masciarelli, Gisella Guerrera, Francesco Fazi, Francesco Lo-Coco, Maria Teresa Voso, Nelida Ines Noguera.

Conclusion

Dr. Serena Travaglini stands as a distinguished emerging researcher in molecular hematology, demonstrating both scientific rigor and translational vision. Her academic excellence, from her foundational training through her innovative postdoctoral and current work, underscores her commitment to unraveling the biological mechanisms underpinning leukemia and resistance. Her strategically focused research on leukemia stem cells, therapeutic biomarker validation, and overcoming drug-resistant APL speaks to her potential to influence next-generation leukemia therapies. Recognition through prestigious awards and notable scholarly contributions further affirm her candidacy. With continued support, Dr. Travaglini is poised to lead impactful research initiatives that can reshape treatment paradigms in acute leukemia and precision medicine.